Preladenant

From WikiMD.org
Jump to navigation Jump to search

Preladenant

Preladenant (pronunciation: pre-lad-en-ant) is a selective antagonist of the adenosine A2A receptor. It was developed by Schering-Plough and later by Merck & Co. for the treatment of Parkinson's disease and other related neurological disorders.

Etymology

The term "Preladenant" is derived from the words "pre" meaning before, and "adenant" which is a shortened form of "adenosine antagonist". The name signifies its function as a pre-emptive blocker of the adenosine A2A receptor.

Function

Preladenant works by selectively blocking the adenosine A2A receptor. This receptor is found in the brain and is involved in the regulation of glutamate and dopamine, two neurotransmitters that are crucial for motor function. By blocking this receptor, Preladenant can help to alleviate the symptoms of Parkinson's disease.

Related Terms

  • Adenosine A2A receptor: A protein that is encoded by the ADORA2A gene in humans. Preladenant is a selective antagonist of this receptor.
  • Schering-Plough: A United States-based pharmaceutical company that developed Preladenant.
  • Merck & Co.: A multinational pharmaceutical company that continued the development of Preladenant after acquiring Schering-Plough.
  • Parkinson's disease: A long-term degenerative disorder of the nervous system that mainly affects the motor system. Preladenant was developed for the treatment of this disease.

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski